Markets & Finance

Curium US Holdings agreed on August 3, 2026 to acquire Lantheus Holdings for $102.50 per share in cash at closing, with contingent value rights tied to sales milestones through 2030 bringing the maximum per-share consideration to $114.50 and the total deal value to approximately $8 billion. The combined company would operate a radiopharmaceutical business spanning diagnostics and therapeutics across more than 70 countries, with the merger expected to close in the first half of 2027 pending shareholder and regulatory approvals. Key deal terms remain undisclosed in the initial filing, including the full merger agreement, named financing sources, specific regulatory jurisdictions, and termination fee figures.

Williams announced on August 3 that it will acquire 100% of Momentum Midstream (M6) for up to $5.5 billion, structured as roughly $3.5 billion in cash and debt plus approximately $2 billion in Williams equity, pending antitrust clearance and customary closing conditions. The deal adds over 4,000 miles of Haynesville pipeline, 6 Bcf/d of system capacity, and connections to more than 140 customers including 10 LNG facilities and 26 power plants. Key transaction mechanics — including the cash-to-debt split, equity issuance details, and the conditions behind the 'up to' ceiling — have not been disclosed in public releases reviewed.

KKR agreed on August 3, 2026, to buy medical-device manufacturer Integer Holdings in an all-cash deal at $127 per share, representing a 51.8% premium to Integer's April 29 closing price. The transaction followed a strategic review Integer's board initiated on April 30, 2026, and was unanimously approved as the option that maximized stockholder value. Closing, expected by end of 2026, requires stockholder approval and regulatory clearances; the deal carries no financing contingency, with funding to come from KKR-managed equity and committed debt arranged by Citi, KKR Capital Markets, Barclays, UBS, and Jefferies.

TotalEnergies has sold a 50% stake in a 1.2 gigawatt European renewables portfolio to private equity firm KKR for €1.8 billion. The transaction reflects ongoing capital recycling strategies among major energy producers, who are increasingly partnering with institutional investors to fund large-scale clean energy assets. The deal values the portfolio at approximately €3.6 billion in total.

Latigo Biotherapeutics filed an amended S-1 with the SEC on August 3, 2026, proposing 16 million shares at $16–$18 each, with estimated net proceeds of $247.2 million at the midpoint intended to fund Phase 3 trials for its lead non-opioid pain candidate LTG-001 and advance a second candidate through Phase 2. The company reported net losses of $61.2 million in 2024 and $109.2 million in 2025, holds $42.2 million in cash as of March 31, 2026, and has acknowledged it will need additional capital beyond this offering. The IPO arrives in a biotech market that saw only six biopharma offerings in Q1 2026, a pace consistent with the prior three years rather than a broad recovery.

BlossomHill Therapeutics has filed amended IPO terms proposing to sell 7,812,500 shares at $15 to $17 each, targeting roughly $111.7 million in net proceeds at the midpoint to fund its oncology pipeline through early 2028. The company's lead candidate, BH-30643, is a mutant-selective EGFR inhibitor in a Phase 1/2 trial across more than 40 sites in 10 countries, with early data described as supportive but not yet quantified in the filing. The offering had not priced or begun trading as of the documents reviewed, making this a preview of proposed terms rather than a report of a completed transaction.

Robinhood Ventures Fund II began its roadshow on August 3, 2026, seeking to raise up to $200 million through an NYSE listing at $25 per share, with no accreditation or net-worth requirements for participation. The fund is structured as a Business Development Company holding stakes in a seed portfolio of 80 private companies across AI, fintech, and robotics, with total estimated annual expenses of 4.18% plus a 4.50% sales load. Key disclosures include no shareholder redemption rights, a pending SEC exemptive order for co-investments, and unreconciled offering-expense estimates in the pre-effective filing.

Marriott International posted Q2 2026 adjusted diluted EPS of $3.19 against a $3.05–$3.08 consensus estimate, while revenue of $7.07 billion missed the $7.19 billion forecast by 1.7%. The company raised its full-year global RevPAR growth guidance to 3.0–3.5% from a prior 2–3% range, with Middle East conflict estimated to reduce full-year global RevPAR growth by approximately 100 basis points. Marriott also confirmed new long-term co-branded credit card agreements with JPMorgan Chase and American Express, projecting an annual fee contribution of $100–$125 million by 2028.

ADM will release its second-quarter 2026 financial results before a 7:30 a.m. Central Time webcast on August 4, with no figures publicly available as of 4:07 a.m. EDT that morning. The release will be measured against ADM's updated full-year adjusted-EPS guidance of $4.15–$4.70, which the company raised after Q1 following U.S. biofuels policy clarity that benefited its crushing and ethanol businesses. Key items to watch include segment operating results across Ag Services & Oilseeds, Carbohydrate Solutions, and Nutrition, along with any revision to full-year guidance.

Gilead Sciences releases its Q2 2026 earnings after market close on August 4, 2026, with a management webcast at 4:30 p.m. ET. The quarter is expected to include an $11.5 billion acquired in-process research and development charge tied to the Arcellx, Ouro, and Tubulis transactions, which already shifted full-year EPS guidance from positive to a projected GAAP loss of $2.85 to $3.25 per share. The release will also update investors on Q1's $6.95 billion product-sales base, HIV franchise growth led by Biktarvy, Trodelvy's 37 percent oncology gain, and the 52 percent decline in Veklury sales against a $600 million full-year target.

MNTN releases its second-quarter 2026 financials after market close on August 4, with management guidance calling for $81 million to $83 million in revenue and $19 million to $22 million in adjusted EBITDA. The report will show whether the company sustained the 81% gross margin and 22% adjusted-EBITDA margin it posted in Q1 2026, and whether its active Performance TV customer count grew beyond the 3,874 recorded on a trailing-12-month basis. Any revision to full-year 2026 guidance of $347 million to $357 million in revenue will also be disclosed at that time.

TransMedics enters its Q2 2026 earnings release with Q1 revenue of $173.9 million, a 21% year-over-year increase, and full-year 2026 guidance of $727 million to $757 million that management reaffirmed after the first quarter. The company's revenue is heavily concentrated in U.S. liver transplant services through its National OCS Program, which accounted for roughly $139 million of Q1's total. The Q2 results, due after market close on August 4, will show whether that growth rate held and whether the annual guidance range is revised.

International Flavors & Fragrances will release its Q2 2026 financial results after market close on August 4, 2026, followed by a management webcast on August 5. The release arrives as IFF operates under a restructured four-segment model following the 2025 divestiture of its Pharma Solutions business and the replacement of its Nourish segment with Food Ingredients, making direct year-over-year comparisons difficult without company-provided restatements. Heading into the report, IFF carried $5.85 billion in total debt and reaffirmed full-year 2026 guidance of $10.5–$10.8 billion in sales, with segment-level margin divergence — notably Scent's unfavorable price-to-input-cost dynamics versus Taste's pricing gains — among the key performance questions the release is expected to address.

Albemarle's Q1 2026 results show net sales of $1,428.7 million, adjusted EBITDA of $663.8 million, and an Energy Storage realized lithium price of $17 per kilogram LCE against a market average of $20. The company's full-year 2026 guidance spans a wide range tied directly to lithium price scenarios, with Energy Storage net sales and EBITDA expected to rise sequentially in Q2 assuming flat market pricing. Q2 results due August 5 will offer the next concrete data point on price transmission, contract-lag effects, and volume across the battery-materials supply chain.

Axon Enterprise posted Q1 2026 revenue of $807 million, a 34% year-over-year increase, with Annual Recurring Revenue of $1.493 billion and future contracted bookings of $14.3 billion, up 44%. The company guided for full-year 2026 revenue growth of 30% to 32%, with international revenue doubling year over year to represent 20% of quarterly sales. Q2 2026 results are scheduled for release on August 5, which will show whether those growth rates held and whether full-year guidance is revised.

AbCellera's Q2 2026 earnings webcast is scheduled for August 5, with Q1 2026 serving as the available financial baseline: revenue of $8.3 million, a net loss of $43.2 million, and operating cash burn of $33.5 million. Readers will also find context on why AbCellera's reported 'total available liquidity' of approximately $655 million differs by roughly $150 million from the $504.7 million in cash and marketable securities on its 10-Q balance sheet. A July 29 collaboration with Vertex to discover multispecific T-cell engagers is among the items whose financial recognition will first appear in the Q2 release.

Xperi will release its second-quarter 2026 financials after market close on August 5, followed by a 5 p.m. EDT earnings call. The report arrives after Q1 2026 showed flat revenue of $114.2 million year over year but a significantly improved GAAP operating income of $2.2 million versus a $16.4 million loss in Q1 2025, alongside a 45% year-over-year rise in Media Platform revenue and negative free cash flow of $22.8 million. Key items to watch include whether TiVo One advertising growth and Connected Car licensing gains continued to offset declines in Pay-TV legacy revenue, and whether cash flow is tracking toward the full-year guidance of $15 million to $25 million in operating cash flow.